Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

FCS and SHTG: Are We Meeting the Need?

2 chapters
Play All
15 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test Skip straight to the post-test if you have already participated in this activity.
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    Patients with familial chylomicronemia (FCS) and severe hypertriglyceridemia (SHTG) suffer from multiple complications, the most severe being acute pancreatitis. Current therapeutic agents, which include fibrates, omega-3 fatty acids, statins, and niacin, are generally ineffective. There are new developments with investigational siRNA therapeutics that silence APOC3, a key regulator of triglycerides and triglyceride-rich lipoproteins. Recent presentations have highlighted outcomes of trials evaluating APOC3 siRNA therapeutics in patients with FCS or SHTG. Drs. Ray, Goldberg, and Ballantyne discuss the findings of these trials, including the PALISADE trial and SHASTA-2 trial with plosaziran, and the potential implications for patients with FCS and SHTG.  

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty: 
    Ira J. Goldberg, MD 
    Professor of Endocrinology
    Director, Division of Endocrinology,
    Diabetes and Metabolism
    NYU Langone Diabetes & Endocrine Associates
    New York, NY

    Dr. Goldberg has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    No relevant relationships reported

    Kausik Ray, FMedSci 
    President, European Atherosclerosis Society
    Director, Imperial Centre for
    Cardiovascular Disease Prevention
    Imperial College London
    London, UK

    Dr. Kausik has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    No relevant relationships reported

    Christie Mitchell Ballantyne, MD 
    Professor of Medicine
    Chief, Cardiovascular Research
    Baylor College of Medicine
    Houston, TX

    Reviewers/Content Planners/Authors:

    • Tim Person has nothing to disclose.
    • Anja Gerrits has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Summarize the latest clinical trial data on novel therapeutic agents for the treatment of FCS
    • Describe the key findings of RCTs on new therapies for the management of SHTG
  • Target Audience

    This activity has been designed to meet the educational needs of cardiologists (lipidologists) and endocrinologists as well as all other physicians and healthcare providers involved in managing patients with FCS and SHTG.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.

  • Commercial Support

    This activity is supported by an independent educational grant from Arrowhead Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medcon International. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medcon International you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
Comments
  • Overview

    Patients with familial chylomicronemia (FCS) and severe hypertriglyceridemia (SHTG) suffer from multiple complications, the most severe being acute pancreatitis. Current therapeutic agents, which include fibrates, omega-3 fatty acids, statins, and niacin, are generally ineffective. There are new developments with investigational siRNA therapeutics that silence APOC3, a key regulator of triglycerides and triglyceride-rich lipoproteins. Recent presentations have highlighted outcomes of trials evaluating APOC3 siRNA therapeutics in patients with FCS or SHTG. Drs. Ray, Goldberg, and Ballantyne discuss the findings of these trials, including the PALISADE trial and SHASTA-2 trial with plosaziran, and the potential implications for patients with FCS and SHTG.  

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty: 
    Ira J. Goldberg, MD 
    Professor of Endocrinology
    Director, Division of Endocrinology,
    Diabetes and Metabolism
    NYU Langone Diabetes & Endocrine Associates
    New York, NY

    Dr. Goldberg has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    No relevant relationships reported

    Kausik Ray, FMedSci 
    President, European Atherosclerosis Society
    Director, Imperial Centre for
    Cardiovascular Disease Prevention
    Imperial College London
    London, UK

    Dr. Kausik has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    No relevant relationships reported

    Christie Mitchell Ballantyne, MD 
    Professor of Medicine
    Chief, Cardiovascular Research
    Baylor College of Medicine
    Houston, TX

    Reviewers/Content Planners/Authors:

    • Tim Person has nothing to disclose.
    • Anja Gerrits has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Summarize the latest clinical trial data on novel therapeutic agents for the treatment of FCS
    • Describe the key findings of RCTs on new therapies for the management of SHTG
  • Target Audience

    This activity has been designed to meet the educational needs of cardiologists (lipidologists) and endocrinologists as well as all other physicians and healthcare providers involved in managing patients with FCS and SHTG.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.

  • Commercial Support

    This activity is supported by an independent educational grant from Arrowhead Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medcon International. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medcon International you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule9 Dec 2024